SASKATOON, Saskatchewan, Sept. 03, 2024 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that, further to its news release dated August 22, 2024, it has completed the acquisition of a 90% interest in a pharmacy (the “Acquired Pharmacy”) located in Western Canada. The acquisition of the Acquired Pharmacy is an arm’s length transaction. The aggregate purchase price for the 90% interest in the Acquired Pharmacy was $2,207,170 and was funded from cash.
The Acquired Pharmacy represents PharmaCorp’s second acquisition following the successful completion of its Qualifying Transaction on June 6, 2024, which included the acquisition of a 75% interest in a pharmacy in Saskatoon, Saskatchewan, as well as the previously announced strategic alliance with PharmaChoice Canada Inc.
“We are pleased to announce the successful completion of the acquisition of the Acquired Pharmacy, reinforcing our strategy to enhance shareholder value through strategic acquisitions,” said Al Simpson, Executive Chairperson of PharmaCorp. “By retaining a vendor to continue managing the pharmacy, we are ensuring seamless continuity and maintaining the high service standards our customers expect, as we continue to grow our presence in the pharmacy industry.”
About PharmaCorp Rx Inc.
As a Capital Pool Company, PharmaCorp completed its qualifying transaction as defined in Policy 2.4 of the TSX Venture Exchange on June 6, 2024. The qualifying transaction consisted of its strategic alliance with PharmaChoice Canada Inc. (“PharmaChoice”) and the acquisition of 75% of the outstanding shares of a pharmacy in Saskatoon, SK. PharmaCorp operates two pharmacies, including the Acquired Pharmacy. PharmaCorp will continue to acquire independently owned and branded PharmaChoice pharmacies as they come to market in the normal course of business, as well as other independently owned non-branded PharmaChoice pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice banner. PharmaCorp trades on the TSX Venture Exchange under the symbol: PCRX.
For further information, contact:
Mr. Alan Simpson
Suite #203, 303 Wellman Lane, Saskatoon, SK S7T 0J1
Tel: (306) 536-3771
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains “forward-looking information” regarding the Corporation within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the potential effects of the 10% retained interest by the vendors; and the business of PharmaCorp, including the operation and acquisition of pharmacies, including the acquisition of independently owned and PharmaChoice branded, and non-PharmaChoice branded, pharmacies. This forward-looking information reflects current beliefs and is based on information currently available to the management of the Corporation and on assumptions the Corporation believes are reasonable. These assumptions include, but are not limited to the continued supply of pharmacies for purchase by PharmaCorp at prices satisfactory to PharmaCorp. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board of directors, third party or regulatory approvals; competition; changes in legislation, including environmental legislation, affecting the Corporation; the timing and availability of external financing on acceptable terms; conclusions of economic evaluations and appraisals; and lack of qualified, skilled labour or loss of key individuals. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Corporation’s disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although the Corporation has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of the Corporation as of the date of this news release and, accordingly, is subject to change after such date. However, the Corporation expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
Bay Street News
